Ensysce Biosciences, Inc. (ENSC)
| Market Cap | 8.14M +33.5% |
| Revenue (ttm) | 6.19M +37.9% |
| Net Income | -91.21M |
| EPS | -8.71 |
| Shares Out | 19.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 418,346 |
| Open | 0.4460 |
| Previous Close | 0.3872 |
| Day's Range | 0.3900 - 0.4460 |
| 52-Week Range | 0.2300 - 2.1650 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 4.08 (+875.86%) |
| Earnings Date | Nov 12, 2026 |
About ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the... [Read more]
Financial Performance
In 2025, Ensysce Biosciences's revenue was $5.07 million, a decrease of -2.75% compared to the previous year's $5.21 million. Losses were -$10.18 million, 27.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ENSC stock is "Strong Buy." The 12-month stock price target is $4.08, which is an increase of 875.86% from the latest price.
News
Ensysce Biosciences Earnings release: Q3 2026
Ensysce Biosciences released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Ensysce Biosciences Quarterly report: Q3 2026
Ensysce Biosciences has published its Q3 2026 quarterly earnings report on November 12, 2026.
Ensysce Biosciences Proxy statement: Proxy filing
Ensysce Biosciences filed a proxy statement on November 12, 2026, providing details for shareholder voting and corporate governance matters.
Ensysce Biosciences initiated with a Buy at UBS
UBS initiated coverage of Ensysce Biosciences (ENSC) with a Buy rating and $2 price target The company offers an “early-stage but differentiated” opportunity in chronic pain, the analyst tells investo...
Ensysce Biosciences Proxy statement: Proxy filing
Ensysce Biosciences filed a proxy statement on October 30, 2026, providing details for shareholder voting and corporate governance matters.
Ensysce Biosciences registers to sell 433.91M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 433.91M shares of common stock. The company is not selling any…
Ensysce Biosciences Registration statement: Registration filing
Ensysce Biosciences filed a registration statement on October 23, 2026, providing details about a securities offering with the SEC.
Ensysce Biosciences participates in Family Office Summit, Dubai
Ensysce Biosciences (ENSC) announced that James Morrison, President of Ensysce Biosciences, participated in the Family Office Summit, Dubai, on October 15, 2026. The visit was a central component of E...
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
~President James Morrison met Middle East family offices as Ensysce advances CY200 and its severe pain pipeline~ SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:...
Ensysce Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage of Ensysce Biosciences (ENSC) with an Overweight rating and $2 price target Ensysce’s acquisition of Cy Biopharma adds CY200, a bota...
Ensysce Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Ensysce Biosciences (ENSC) with an Overweight rating and $2 price target
Ensysce Biosciences submits Phase 2 protocol for CY200 to UK MHRA
Ensysce Biosciences (ENSC) announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company’s newest drug candidate from the newly acquired Cy Biopharma. This milestone…
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC...
Ensysce Biosciences advances CRPS program at Painweek 2026
Ensysce Biosciences (ENSC) hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals. Dr. Jeff Gudin provided background on the Ensysce novel progr...
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic the...
Ensysce professor to speak at FDA public hearing on psychedelic drugs
Ensysce Biosciences (ENSC) announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. Food and Drug Administration’s public hearing, “Co...
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic the...
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic ther...
Ensysce completes enrollment for final phase of PF614-MPAR-102 study
Ensysce Biosciences (ENSC) announced completion of enrollment in the final stage of the PF614-MPAR-102 clinical study. The study evaluated its novel MPAR overdose-protection technology. Unlike traditi...
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce...
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~ ~Discussions to feature a first-in-class approach to neural reset and novel chemical s...
Ensysce Biosciences Transcript: Investor update
Announced the acquisition of Cy Biopharma and up to $77 million in financing to advance CY200, a novel therapy for CRPS, through key clinical milestones. Integration brings new leadership and extends cash runway into late 2027.
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome Up to $77 million in new funding with the acquisition of Cy Biopharma Company to host a Corporate Update Call on ...
Ensysce Biosciences Earnings release: Q2 2026
Ensysce Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Ensysce Biosciences Quarterly report: Q2 2026
Ensysce Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.